July 16, 2012 | Vol. 11 No. 138 | Full Issue in PDF Format
View the entire issue.
Drug manufacturers in the Indian states of Haryana and Uttar Pradesh are more likely to produce substandard or falsified drugs than those in more regulated Indian states, an expert tells DID.
Sanofi Pasteur has suspended production at its Toronto, Canada, plant to address mold troubles that recently landed the drugmaker an FDA Form 483 and prompted global shortages of a tuberculosis (TB) vaccine and a bladder cancer treatment produced there, the company says.
GlaxoSmithKline (GSK) and Theravance have submitted applications in the U.S. and European Union (EU) for a new chronic obstructive pulmonary disease (COPD) and asthma treatment.
The FDA has appointed a former industry executive for the long-vacant top spot at Office of Generic Drugs (OGD).
The FTC again is asking for more information from Watson Pharmaceuticals on its proposed $5.6 billion merger with Actavis, delaying its attempt to become the world’s third largest generic-drug company.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.